IRLAB Therapeutics: IRL757 reports positive Ph 1 - ABG

Apathy drug candidate completed Ph 1 in elderly adults
Positive PK, safety and tolerability data confirmed
2nd Ph 1 in younger adults to finish in H1'25


IRL757 finishes Ph 1 in 65+ healthy adults

Today IRLAB announced positive topline results from IRL757 in healthy adults aged 65 and older. Most importantly, the study confirmed the drug candidate's favourable PK, safety and tolerability profile observed already in part 1 of the study in healthy younger adults. The study was part of the collaboration with MSRD.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2025/1/irlab-therapeutics---irl757-reports-positive-ph-1/